Balaxi Pharmaceuticals Limited · NSE:BALAXI
Balaxi Pharmaceuticals — Q3 FY2022 Earnings Presentation
49 slides from Balaxi Pharmaceuticals's earnings presentation, Feb 15, 2022
Slide 1: Covering letter to NSE for Investor Presentation Q3 & 9M FY22
Balaxi area et glass Limited To 15 February, 2022 Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot No C/1, G Block, BKC, Bandra (E), Mumbai-400051 Stock Code: BALAXI Sub: Investor Presentation-Q3 & 9M FY 2021-22 Dear Sir/ Madam, We hereby attach the Investor Presenta
Slide 2: Investor Presentation
Page - 01 B A L A X I P H A R M A C E U T I C A LS L I M I T E D INVESTOR PRESENTATION
Slide 3: Disclaimer
Page - 02 B A L A X I P H A R M A C E U T I C A LS L I M I T E D Disclaimer This presentation and the following discussion may contain “forward-looking statements” by “Balaxi Pharmaceuticals Limited” that are not historical in nature. Such forward-looking statements are subject to certain risks and
Slide 4: Q3 & 9MFY22 Result Highlights
Page - 03 » Q3& 9MFY22 Result Highlights » Business Strategy » Industry & Outlook » Business Overview » Financial Highlights INVESTOR B A L A X I P H A R M A C E U T I C A LS L I M I T E D PRESENTATION Q3 & 9MFY22 RESULT HIGHLIGHTS
Slide 5: Quick Overview
Page - 04 Q3 FY22: Quick Overview Revenue for EBITDA higher 11% PAT higher 18% YoY pharmaceuticals grown by % YoY to INR 132 mn Q9MFY22 31% Pharmaceuticals Business Gross profit of INR contributes 74% of the 28:72 197million registering a consolidated revenues and (Branded:Generics) 19.3% growth yea
Slide 6: Consolidated Financial Highlights
Page - 05 Q3FY22: Consolidated Financial Highlights In INR Mn Gross Profit (YoY) EBITDA & EBITDA Margin (YoY) PAT & PAT Margin (YoY) 132 122 23.0% 22.0% 110 19.7% 197 119 165 21.0% 21.0% 19.3% 20.0% 11% 11% 19.0% 18.0% 18.0% 16.6% 17.0% 16.0% 15.0% Q3FY21 Q3FY22 Q3FY21 Q3FY22 Q3FY21 Q3FY22 • Company
Slide 7: Consolidated Profit and Loss Statement
Page - 06 Consolidated Profit and Loss Statement Particulars (In INR Mn) Q3FY22 Q3FY21 YoY % 9MFY22 9MFY21 YoY% FY21 Revenue From Operations 617 660 -6% 1,902.9 1,783.8 7% 2,313.331 Other Income -4 3 -228% 9.1 25.1 -64% 22.3 Total Income 613 663 -8% 1,912 1,808.9 6% 2,335.6 COGS 420 495 -15% 1,346.1
Slide 8: Consolidated Balance Sheet
Page - 07 Consolidated Balance Sheet Particulars (In INR Mn) 9MFY22 Particulars (In INR Mn) 9MFY22 Shareholder's Funds 1009.06 Non-Current Assets 142.87 Equity Share Capital 100.00 Fixed Assets – Tangible & Intangible 33.80 Reserves & Surplus 909.06 CWIP & Intangibles under development - Minority In
Slide 9: Segment Revenue Breakup
Page - 08 Segment Revenue Breakup Revenue Mix % (Q3FY22) Revenue Mix % (Q3FY21) 22% 34% 3% 53% 74% 13% Pharmaceuticals Branded Consumer Products Ancillary Pharmaceuticals Branded Consumer Products Ancillary
Slide 10: Business Segment Financial Highlights
Page - 09 Q3FY22: Business Segment Financial Highlights In INR Mn Revenue Gross Profit Gross Profit Margin 458 37% 170 32% 350.1 111.0 222 19% 17% 18% 139 88 38 6% 26 16 20 1 Q3FY22 Q3FY21 Q3FY22 Q3FY21 Q3FY22 Q3FY21 Pharmaceuticals Pharmaceuticals Pharmaceuticals Ancillary Ancillary Ancillary Brand
Slide 11: Company Overview
Page - 12 » Q3 & 9MFY22Result Highlights » Company Overview » Business Strategy » Industry & Outlook » Business Overview INVESTOR B A L A X I P H A R M A C E U T I C A LS L I M I T E D PRESENTATION COMPANY OVERVIEW
Slide 12: Vision Mission
Page - 11 Balaxi Pharmaceuticals: Bridging the supply chain gap in frontier markets B A L A X I P H A R M A C E U T I C A LS L I M I T E D We are a branded IPR-based pharmaceuticals Company focusing on frontier markets, with a vast and growing portfolio of drugs across multiple therapeutic segments.
Slide 13: Values Purpose
Page - 12 Balaxi Pharmaceuticals: Bridging the supply chain gap in the frontier markets B A L A X I P H A R M A C E U T I C A LS L I M I T E D Our value system is the foundation for transparency and strong corporate governance. While we create value for shareowners, we work ethically and honestly to
Slide 14: Global Presence With Localisation
Page - 13 Balaxi Pharmaceuticals: Global Presence With Localisation B A L A X I P H A R M A C E U T I C A LS L I M I T E D A growing pharmaceuticals company with on-ground presence in markets within Africa, Caribbean Islands & Latin America Headquartered in Hyderabad, India, we are an IPR-driven ass
Slide 15: The Company's Evolution
Page - 14 Our Genesis: The Company’s Evolution B A L A X I P H A R M A C E U T I C A LS L I M I T E D Pre 2017 » The Company was listed on NSE in 2015 as ‘The Anandam Rubber Company Ltd’ 2017-2019 » In March, 2017, the Company was taken over by Balaxi Group, a prominent pharmaceuticals player in Ang
Slide 16: Balaxi Group's Journey
Page - 15 Our Genesis: Balaxi Group’s Journey B A L A X I P H A R M A C E U T I C A LS L I M I T E D 2003-07 2008-10 2011-13 2014-16 2017-19 2020-2021 » Commenced » Created front-end » Started sourcing » In 2014, the Group » Setup central » Submitted several Pharmaceuticals presence for its pharmace
Slide 17: Business Strategy
Page - 18 » Q2 & H1 FY22 Result Highlights » Company Overview » Business Strategy » Industry & Outlook » Business Overview INVESTOR B A L A X I P H A R M A C E U T I C A LS L I M I T E D PRESENTATION BUSINESS STRATEGY
Slide 18: Our Approach For Creating Value
Page - 17 How We Operate: Our Approach For Creating Value B A L A X I P H A R M A C E U T I C A LS L I M I T E D 1 2 3 4 5 6 Intellectual Robust Product Asset-Light Geographical Focus on Brand Property Infrastructure & Registrations Production Footprint Equity Research Logistics » Balaxi undertakes
Slide 19: Straddling The Value Chain
Page - 18 How We Operate: Straddling The Value Chain B A L A X I P H A R M A C E U T I C A LS L I M I T E D Market & Product Selection We focus on bringing essential medicines within the reach of populations within frontier markets, which are challenging Market Research to penetrate. In particular,
Slide 20: Our Strengths "Built Over Time"
Page - 19 Balaxi’s Key Differentiators: Our Strengths “Built Over Time” B A L A X I P H A R M A C E U T I C A LS L I M I T E D Four ‘E’s differentiates BALAXI 1 Experience Two Decades of versatile experience of the BALAXI group ensures flawless execution. 19 years Angola, Dominican Entry into The Co
Slide 21: The making of a Pharmaceuticals Major in multiple Frontier Markets
Page - 20 Investing In Balaxi: The making of a Pharmaceuticals Major in multiple Frontier Markets B A L A X I P H A R M A C E U T I C A LS L I M I T E D » The Company participates in all stages of the pharma value chain, except in the R&D and manufacturing stages. Instead, it prefers to register pro
Slide 22: The making of a Pharmaceuticals Major in multiple Frontier Markets (contd.)
Page - 21 Investing In Balaxi: The making of a Pharmaceuticals Major in multiple Frontier Markets (contd.) B A L A X I P H A R M A C E U T I C A LS L I M I T E D 3 » The focus on the Company’s ‘cash & carry’ » The Company presently operates in three main regions Angola, Dominican model ensures regul
Slide 23: An Asset-Light Business Model Focussed on IPR's
Page - 22 Balaxi Pharmaceuticals: An Asset-Light Business Model Focussed on IPR’s B A L A X I P H A R M A C E U T I C A LS L I M I T E D Pharmaceuticals Industry Value Chain Balaxi’s Operating Areas Research & Drug Market Product Market & Pharmacy Registrations Manufacturing Development Discovery Re
Slide 24: Pharmaceuticals Business Overview
Page - 23 Pharmaceuticals Business Overview B A L A X I P H A R M A C E U T I C A LS L I M I T E D 26% are Anitbiotic » The Company has a healthy ratio of branded and generic medicines in its portfolio of 28:72 (Branded: Generics) in Q3FY22 » The Company is in the business of supplying everyday medi
Slide 25: Inherent Strategy Built Over Time Leading To Strong Brand Presence
Page - 24 Pharma Product Portfolio: Inherent Strategy Built Over Time Leading To Strong Brand Presence Geographical Mix % (Q3FY22) Geographical Mix % (Q3FY21) • As company expands it different geographies, share of other countries has improved accordingly. Revenue 0.0% growth was witnessed across al
Slide 26: Product Mix & Categories 1/2
Page - 25 Pharma Product Portfolio: Product Mix & Categories 1/2 Product Mix % (Angola) Product Mix % (Guatemala) Product Mix % (Dominican Republic) 14% 11% 51% 49% 86% 89% Branded Generics Branded Generics Branded Generics Product Category Mix % (Angola) Product Category Mix % (Guatemala) Product C
Slide 27: Product Mix & Categories 2/2
Page - 26 Pharma Product Portfolio: Product Mix & Categories 2/2 Therapeutic Area % (Angola) Therapeutic Area % (Guatemala) Therapeutic Area % (Dominican Republic) 26% 32% 27% 38% 41% 55% 21% 18% 15% 27% Antibiotics Analgesic Anti Malaria Others Antibiotics Analgesic Others Antibiotics Analgesic Oth
Slide 28: Our Offerings - 300+ products across multiple Therapeutic Areas
2 Page - 7 Pharma Product Portfolio: Our Offerings- 300+ products across multiple Therapeutic Areas
Slide 29: Glimpse of Our Products
Page - 28 Glimpse of Our Products B A L A X I P H A R M A C E U T I C A LS L I M I T E D
Slide 30: Glimpse of Our Products - Branded Consumer Products
Page - 29 Glimpse of Our Products - Branded Consumer Products B A L A X I P H A R M A C E U T I C A LS L I M I T E D
Slide 31: Adding New Geographies and Extensive Presence Through Robust On-Ground Infrastructure
Page - 30 “Our Land & Expand Strategy”: Adding New Geographies and Extensive Presence Through Robust B A L A X I P H A R M A C E U T I C A LS L I M I T E D On-Ground Infrastructure Our current established markets are Angola, Guatemala and Dominican Republic, where we have a strong presence in terms
Slide 32: Balaxi Pharmaceuticals Group Structure
Page - 31 Balaxi Pharmaceuticals Group Structure B A L A X I P H A R M A C E U T I C A LS L I M I T E D Balaxi Pharmaceuticals Limited Balaxi Global DMCC, Dubai (WOS) Balaxi Balaxi Balaxi Balaxi Balaxi Balaxi YAP, Balaxi Balaxi Balaxi Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Slide 33: Industry & Outlook
Page - 34 » Q3 & 9M FY22 Result Highlights » Company Overview » Business Strategy » Industry & Outlook » Business Overview INVESTOR B A L A X I P H A R M A C E U T I C A LS L I M I T E D PRESENTATION INDUSTRY & OUTLOOK
Slide 34: Macro Economy & Industry Data
Page - 33 New Geographies: Macro Economy & Industry Data Macro Economic Data as on 2020 • Central American countries reported US$ 2,625 million of pharmaceuticals S&P Credit GDP Per imports between January to September 2020. GDP * GDP Population Inflation Country Rating Capita * (US$ bn) Growth % (m
Slide 35: Enter, Expand and Excel
Page - 34 Future Roadmap: Enter, Expand and Excel B A L A X I P H A R M A C E U T I C A LS L I M I T E D The Company aims to establish its presence and expand in 20 frontier markets over the next 5 years. Balaxi In 2021-22 - Balaxi In 2020 Expansion In New – Business Geographies. Balaxi In 2023 & Co
Slide 36: Robust Pipeline Ahead
Page - 35 Pharma Products Registrations*: Robust Pipeline Ahead Submitted to Ministry Existing Registrations* of Health (MOH) Pipeline Dominican Republic 20 • 168 Registrations* Submitted to Ministry of Health (MOH) 585 Registrations as on date • 413 Registrations* in Pipeline Angola comprises of 49
Slide 37: Business Overview
Page - 38 » Q3 &9MFY22 Result Highlights » Company Overview » Business Strategy » Industry & Outlook » Business Overview INVESTOR B A L A X I P H A R M A C E U T I C A LS L I M I T E D PRESENTATION BUSINESS OVERVIEW
Slide 38: Leading Supplier Of Formulations in Angola, Guatemala and Dominican Republic
Page - 37 Pharmaceuticals Business: Leading Supplier Of Formulations in Angola, Guatemala and B A L A X I P H A R M A C E U T I C A LS L I M I T E D Dominican Republic An IPR-driven pharma company with an asset-light, stock & sell model supplying branded & generic medicines in frontier markets. Ango
Slide 39: Leading Pharmaceuticals Player in Angola
Page - 38 Pharmaceuticals Business: Leading Pharmaceuticals Player in Angola Industry Snapshot Product Sourcing Mix % as of FY21 • Angola is the second largest oil producer in Africa with a population of ~32 million in 2019. 39% 37% • The GDP per capita is US$3,100.00 in 2021. • Angola witnessed pha
Slide 40: Leading Pharmaceuticals Player in Guatemala
Page - 39 Pharmaceuticals Business: Leading Pharmaceuticals Player in Guatemala Product Sourcing Mix % as of FY21 Industry Snapshot • Guatemala is part of the Latin American-Dominican Republic Free Trade Agreement (CAFTA-DR) which includes the United States and 6 Latin American countries. 32% • Guat
Slide 41: Leading Pharmaceuticals Player in Dominican Republic
Page - 40 Pharmaceuticals Business: Leading Pharmaceuticals Player in Dominican Republic Industry Snapshot Product Sourcing Mix % as of FY21 • Dominican Republic is part of the Central American-Dominican Republic Free Trade Agreement (CAFTA- DR) which includes the United States and 6 Central America
Slide 42: Encashing Our On-Ground Infrastructure
Page - 41 Ancillary Business: Encashing Our On-Ground Infrastructure Industry Snapshot Product Mix % as of FY21 • Angolan real estate market is largely dependent on state investments. 25% • Property market continues to be seen as a safe-haven investment in the face of currency devaluation. • Builder
Slide 43: An Emerging Business
Page - 42 Branded Consumer Products: An Emerging Business Industry Snapshot Product Mix % as of FY21 1% • Angola is one of the most promising consumer-goods market in Africa. 7% • Angola imports most of its consumer goods and utilities from countries such as Portugal, Brazil, China 1% and South Afri
Slide 44: Leadership Team
Page - 43 Strong Management: Leadership Team B A L A X I P H A R M A C E U T I C A LS L I M I T E D Ashish Maheshwari Pranav Maheshwari Paridhi Maheshwari Chairman & Managing Director Head – Latin America Head – Branded Consumer Products Founder of the company BBA and Economics Graduate from Emory B
Slide 45: Leadership Team
Page - 44 Strong Management: Leadership Team B A L A X I P H A R M A C E U T I C A LS L I M I T E D Amol Mantri Ram Chawla CFO Country Head – Angola Qualified Chartered Accountant and Certified Public Associated with the Balaxi Group since 2009 Accountant from USA Inherently talented in person to pe
Slide 46: Dynamic Regional Team
Page - 45 Strong Management: Dynamic Regional Team B A L A X I P H A R M A C E U T I C A LS L I M I T E D Angola Guatemala Dominician Republic Jignesh Dinesh Kumar Shah Pankaj Singh Karan Kapoor Finance Controller Head of Operations Head of Operations Laksh Shewakramani Manish Jumnani Bharat Jawaran
Slide 47: Board of Directors
Page - 46 Strong Governance: Board of Directors B A L A X I P H A R M A C E U T I C A LS L I M I T E D Ashish Maheshwari Minoshi Maheshwari Chairman & Managing Director Non-Executive Director Founder of the company Co-Founder of the company First generation entrepreneur and a qualified A commerce gr
Slide 48: Board of Directors
Page - 47 Strong Governance: Board of Directors B A L A X I P H A R M A C E U T I C A LS L I M I T E D Kunal Bhakta Gandhi Gamji M.S Rao Purnima Singh Kamble Independent Director Independent Director Independent Director Independent Director A Chartered Accountant with 15 years of MBA and BE in Engi
Slide 49: Thank You!
THANK YOU! B A L A X I P H A R M A C E U T I C A LS L I M I T E D Balaxi Pharmaceuticals Limited www.balaxipharma.in Chinta Shalini Compliance Officer Email: secretarial@balaxi.in IR Consultants Chintan Mehta IR Consultants - Dickenson World Contact No: +91 98921 83389 Email: balaxi@dickensonworld.c
Balaxi Pharmaceuticals — Q3 FY2022 Earnings Presentation on 6ix